biotech news today obesity drugs glp-1 The race may have a new contender. ๐ Regeneron reported Phase 3 data showing its drug candidate delivered up to 19.3% weight loss at 48 weeks, approaching the efficacy seen Lilly is now pharma's top
Description
During this period, discussions around microdosing GLP-1 began circulating on social media and online forums
The risk-benefit calculation for semaglutide remains favorable for most patients with obesity or type 2 diabetes, conditions that carry their own serious long-term health risks
Chromatography was performed with an AKTAexplorer 10 S fast protein liquid chromatography (FPLC) system (GE Healthcare Life Sciences)
These fats are also great for supporting your overall health
